Ascendis Pharma A/S $ASND Shares Purchased by Hantz Financial Services Inc.

Hantz Financial Services Inc. boosted its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 291.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 352 shares of the biotechnology company’s stock after purchasing an additional 262 shares during the quarter. Hantz Financial Services Inc.’s holdings in Ascendis Pharma A/S were worth $61,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ASND. Compagnie Lombard Odier SCmA acquired a new position in Ascendis Pharma A/S in the second quarter valued at approximately $39,000. Brooklyn Investment Group boosted its holdings in Ascendis Pharma A/S by 332.9% in the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 273 shares in the last quarter. LVW Advisors LLC acquired a new position in Ascendis Pharma A/S in the second quarter valued at approximately $202,000. Dearborn Partners LLC acquired a new position in Ascendis Pharma A/S in the first quarter valued at approximately $203,000. Finally, R Squared Ltd acquired a new position in Ascendis Pharma A/S in the second quarter valued at approximately $209,000.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $197.75 on Thursday. Ascendis Pharma A/S has a one year low of $118.03 and a one year high of $216.45. The business has a fifty day moving average of $201.49 and a two-hundred day moving average of $182.82. The company has a market cap of $12.20 billion, a P/E ratio of -38.32 and a beta of 0.44.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.49. The business had revenue of $216.28 million during the quarter, compared to analyst estimates of $163.17 million. Sell-side analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. UBS Group reissued a “buy” rating and issued a $307.00 price objective (up from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Wall Street Zen raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Finally, Bank of America increased their price objective on Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $249.80.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.